Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis

doi:10.1016/j.jaad.2020.10.071

Meta-Analysis

. 2021 Mar;84(3):871-875.

doi: 10.1016/j.jaad.2020.10.071. Epub 2020 Oct 31.

Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis

Bernice Y Yan¹, Gloria Wasilewski², Mario E Lacouture³, Christopher A Barker⁴

Affiliations

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
² Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: barkerc@mskcc.org.

PMID: 33137440
PMCID: PMC7897249
DOI: 10.1016/j.jaad.2020.10.071

Meta-Analysis

Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis

Bernice Y Yan et al. J Am Acad Dermatol. 2021 Mar.

. 2021 Mar;84(3):871-875.

doi: 10.1016/j.jaad.2020.10.071. Epub 2020 Oct 31.

Authors

Bernice Y Yan¹, Gloria Wasilewski², Mario E Lacouture³, Christopher A Barker⁴

Affiliations

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
² Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: barkerc@mskcc.org.

PMID: 33137440
PMCID: PMC7897249
DOI: 10.1016/j.jaad.2020.10.071

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Lacouture has consulted for Janssen and Seattle Genetics. Dr Barker has received grants from Merck, Amgen, and Elekta; personal fees and nonfinancial support from Driver Group, Regeneron, and Pfizer; and grants and nonfinancial support from Alpha Tau Medical, outside the submitted work. Dr Yan and Author Wasilewski have no conflicts of interest to declare.

Figures

**Figure 1.**
Flow diagram of study selection.

See this image and copyright information in PMC

Cited by

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.
Zhao X, Gao F, Yang J, Fan H, Xie Q, Jiang K, Gong J, Gao B, Yang Q, Lei Z. Zhao X, et al. Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022. Front Oncol. 2022. PMID: 35814436 Free PMC article.

References

1. Geisler AN, Phillips GS, Barrios DM, et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.03.132 - DOI - PMC - PubMed
1. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–e128. doi:10.1016/j.jaad.2012.12.963 - DOI - PubMed
1. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer Oxf Engl 1990. 2016;60:12–25. doi:10.1016/j.ejca.2016.02.010 - DOI - PMC - PubMed
1. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708–720. doi:10.1016/j.jaad.2013.06.038 - DOI - PMC - PubMed
1. Rosen AC, Case EC, Dusza SW, et al. Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi:10.1007/s40257-013-0021-0 - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Geisler AN, Phillips GS, Barrios DM, et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.03.132 - DOI - PMC - PubMed

[2] Geisler AN, Phillips GS, Barrios DM, et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.03.132 - DOI - PMC - PubMed

[3] Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–e128. doi:10.1016/j.jaad.2012.12.963 - DOI - PubMed

[4] Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–e128. doi:10.1016/j.jaad.2012.12.963 - DOI - PubMed

[5] Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer Oxf Engl 1990. 2016;60:12–25. doi:10.1016/j.ejca.2016.02.010 - DOI - PMC - PubMed

[6] Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer Oxf Engl 1990. 2016;60:12–25. doi:10.1016/j.ejca.2016.02.010 - DOI - PMC - PubMed

[7] Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708–720. doi:10.1016/j.jaad.2013.06.038 - DOI - PMC - PubMed

[8] Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708–720. doi:10.1016/j.jaad.2013.06.038 - DOI - PMC - PubMed

[9] Rosen AC, Case EC, Dusza SW, et al. Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi:10.1007/s40257-013-0021-0 - DOI - PubMed

[10] Rosen AC, Case EC, Dusza SW, et al. Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi:10.1007/s40257-013-0021-0 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis

Affiliations

Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources